The relation between neurodegeneration and other pathology in multiple sclerosis: an in vivo MRI study

The relation between neurodegeneration and other pathology in multiple sclerosis: an in vivo MRI study - The relation between neurodegeneration and other pathology in MS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36150

Enrollment

Registered

2011-08-03

Start date

2012-07-31

Completion date

Unknown

Last updated

2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MS multiple sclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age 18-65 years - Clinically definite MS (based on Polman criteria, 2005) - Need to meet the safety criteria to undergo an MRI examination

Exclusion criteria

Exclusion criteria: For all participants: - History of drug abuse - Psychiatric disease - Claustrophobia - Pregnancy - Foreign non MR compatible metal objects in the body - Foreign metal objects in or close to the head;Aditionally for the patients: - Other neurological disorders besides MS - Relapses and/or steroid treatment in the four weeks prior to the examination;Additionally for the healthy controls: - Neurological disorders

Design outcomes

Primary

Measure	Time frame
Global and local atrophy measures will be obtained from high resolution T1-weighted images. Conventional MR images of the brain and spinal cord, and 3D DIR images will be used to detect and classify MS lesions. Advanced MRI techniques, namely DTI and T1 relaxation-time mapping, will be used to quantify tissue damage in normal appearing brain tissue, and relations between these parameters will be assessed.	—

Measure

Time frame

Global and local atrophy measures will be obtained from high resolution T1-weighted images. Conventional MR images of the brain and spinal cord, and 3D DIR images will be used to detect and classify MS lesions. Advanced MRI techniques, namely DTI and T1 relaxation-time mapping, will be used to quantify tissue damage in normal appearing brain tissue, and relations between these parameters will be assessed.

—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results